MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To judge multiple intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Main trial goals were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, even though one of several explora... https://epz00477722109.blue-blogs.com/37819204/parp-1-in-3-secrets